Search Results
Nov 28, 2025, 07:00 ET Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
WASHINGTON, Nov. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness:
More news about: Vanda Pharmaceuticals Inc.
Nov 17, 2025, 18:37 ET Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced positive topline results
More news about: Vanda Pharmaceuticals Inc.
Nov 05, 2025, 17:00 ET Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City on Wednesday, November 12, 2025. A corporate
More news about: Vanda Pharmaceuticals Inc.
Oct 29, 2025, 16:01 ET Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2025.
More news about: Vanda Pharmaceuticals Inc.
Oct 22, 2025, 16:30 ET Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes.
More news about: Vanda Pharmaceuticals Inc.
Oct 08, 2025, 08:00 ET Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
Vanda Pharmaceuticals (Nasdaq: VNDA), a leading global biopharmaceutical company headquartered in Washington, D.C., as the organization's newest Founding Partner for its next-generation
More news about: Monumental Sports & Entertainment
Oct 01, 2025, 17:02 ET Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug Administration (FDA) for the resolution of certain disputes
More news about: Vanda Pharmaceuticals Inc.
Sep 25, 2025, 08:00 ET Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
WASHINGTON, Sept. 25, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia:
More news about: Vanda Pharmaceuticals Inc.
Aug 28, 2025, 17:23 ET Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
WASHINGTON, Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in September 2025:
More news about: Vanda Pharmaceuticals Inc.
Aug 28, 2025, 07:00 ET Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
WASHINGTON, Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based
More news about: Vanda Pharmaceuticals Inc.
Aug 21, 2025, 16:40 ET Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®
WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has asked Martin Makary, the Commissioner of the U.S. Food and Drug Administration (FDA) to review the decision made by Jacqueline
More news about: Vanda Pharmaceuticals Inc.
Aug 18, 2025, 07:00 ET In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding
More news about: Vanda Pharmaceuticals Inc.
Jul 31, 2025, 07:30 ET Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.
More news about: Vanda Pharmaceuticals Inc.
Jul 23, 2025, 16:45 ET Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens.
More news about: Vanda Pharmaceuticals Inc.
Jun 10, 2025, 08:00 ET Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
WASHINGTON, June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide
More news about: Vanda Pharmaceuticals Inc.